[
  {
    "question": "55 y/o male, hx of lower limbs weakness for days, initially started with numbness and tingling, days later started to involve upper limbs, associated with hyperhydrosis in lbs and involve face And Hx of epigastric pain. Examination bilateral LL weakness Hx of influenza vaccine 2 weeks prior to onset\n\nWhat is the diagnosis",
    "option_a": "AIP",
    "option_b": "AIDP",
    "option_c": "Acute spinal",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain\u2013Barr\u00e9 syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy. Its most common variant in Western countries is AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy), which typically presents with an ascending pattern of weakness following an antecedent trigger such as an infection or vaccine. The condition is immune-mediated, with antibodies attacking peripheral nerve myelin (and sometimes axons) after molecular mimicry between components of infectious agents or vaccine antigens and peripheral nerve components. This results in demyelination, slowed nerve conduction, and in severe cases, secondary axonal loss. Patients usually present with paresthesias and numbness starting in the lower limbs, progressing upward to involve the upper limbs and sometimes facial muscles. Autonomic dysfunction (e.g., hyperhidrosis) is common. A history of a preceding event such as an influenza vaccine 2 weeks earlier further supports the diagnosis. Diagnosis is based on clinical presentation, supported by nerve conduction studies (which show evidence of demyelination) and cerebrospinal fluid analysis (classically showing an albuminocytologic dissociation). Differential diagnoses include acute spinal cord lesions, metabolic neuropathies, and less commonly acute intermittent porphyria (AIP), which lacks the classic ascending paralysis pattern. First-line management involves immunomodulatory therapy with either IVIG or plasmapheresis, which has been shown to hasten recovery. Supportive care, including monitoring respiratory function and autonomic instability, is critical. In pregnancy, IVIG is generally considered safe and is the preferred treatment modality, while plasmapheresis can be used if necessary with careful monitoring. Option A (AIP) is less likely because although AIP can cause neuropathic symptoms and abdominal pain, it does not typically present with an ascending symmetric paralysis and recent vaccination history. Option C (Acute spinal) would usually present with a more localized neurologic deficit rather than the classic ascending distribution seen in GBS. Thus, option B (AIDP) best fits the clinical scenario. 1. An antecedent event such as a viral illness or vaccination is common in GBS. 2. The presence of autonomic dysfunction (e.g., hyperhidrosis) is a red flag for potential complications. 3. Early treatment with IVIG or plasmapheresis can improve outcomes. Recent guidelines emphasize early recognition and treatment with IVIG or plasmapheresis to reduce morbidity. Updated studies also highlight the importance of monitoring for respiratory compromise and autonomic instability, with IVIG being favored in pregnant patients due to its safety profile.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "pt with urinary incontinnccae and sx suggesting autonomic with painful neuropathy NCS : axonal neuropathy with CTS Investigation :",
    "option_a": "Abdominal fat pad",
    "option_b": "electrophoresis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients with neuropathy that includes both painful sensory disturbances and autonomic dysfunction (like urinary incontinence), systemic amyloidosis is an important consideration. Carpal tunnel syndrome is a common early manifestation of amyloid deposition in the wrist. Amyloidosis involves deposition of misfolded protein fibrils in various tissues. In AL (primary) amyloidosis, light chains deposit in tissues, including peripheral nerves, leading to axonal damage and neuropathy. Autonomic fibers can also be affected, causing dysautonomia. The clinical presentation of a painful neuropathy with autonomic symptoms, coupled with carpal tunnel syndrome, is characteristic of amyloid neuropathy. Nerve conduction studies showing an axonal pattern further support the involvement of small fibers typical for amyloid deposition. Abdominal fat pad biopsy is a minimally invasive and sensitive method to detect amyloid deposition using Congo red staining. Although electrophoresis (serum or urine immunofixation) can identify a monoclonal protein and support the diagnosis of AL amyloidosis, tissue confirmation is essential. Differential diagnoses include diabetic neuropathy and other small fiber neuropathies, which have different clinical contexts. Management of amyloidosis involves treating the underlying plasma cell dyscrasia (for AL amyloidosis) often with chemotherapy and novel agents like daratumumab. Supportive care for neuropathy is also needed. In pregnancy and lactation, management requires a multidisciplinary approach due to potential teratogenicity of some chemotherapeutic agents; treatment may be deferred or altered based on the risk\u2013benefit assessment. Option A (Abdominal fat pad biopsy) is the appropriate investigation as it directly demonstrates amyloid deposition. Option B (electrophoresis) can support the diagnosis by revealing monoclonal proteins but does not confirm tissue deposition, making option A the more definitive test. 1. Autonomic involvement with a painful, axonal neuropathy should prompt evaluation for systemic amyloidosis. 2. Carpal tunnel syndrome in this setting is a common early clue. 3. Abdominal fat pad biopsy is a highly useful and minimally invasive test to establish the diagnosis. Recent research confirms that abdominal fat pad aspirate, when combined with advanced staining techniques, improves diagnostic sensitivity for amyloidosis. Guidelines also stress the importance of early diagnosis to guide treatment before irreversible organ damage occurs.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "baby, hx of hypotonia, cardiomegaly and macroglossia CK high\n\nWhat is the diagnosis",
    "option_a": "Acid maltase (pompe)",
    "option_b": "Phosphofructokinase",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Pompe disease, or glycogen storage disease type II, is a lysosomal storage disorder caused by a deficiency of the enzyme acid alpha-glucosidase (acid maltase). The enzyme deficiency leads to the accumulation of glycogen in lysosomes, particularly in cardiac and skeletal muscles. This results in muscle weakness, hypotonia, cardiomegaly, and macroglossia. Elevated CK levels reflect ongoing muscle damage. Infants with Pompe disease typically present with profound hypotonia, feeding difficulties, macroglossia, and hypertrophic cardiomyopathy. The high CK level further supports a myopathic process. In contrast, other metabolic myopathies like those due to phosphofructokinase deficiency usually present later with exercise intolerance rather than early cardiomyopathy. The diagnosis is established by demonstrating reduced acid maltase activity in blood, muscle, or fibroblasts along with supportive clinical findings. Genetic testing confirms the diagnosis. Differential diagnoses include other congenital myopathies or storage diseases, but the combination of cardiomegaly and macroglossia is distinct for Pompe disease. The mainstay of treatment is enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase, which should be started as early as possible to improve outcomes. Supportive care includes cardiac management and nutritional support. In pregnancy and lactation, genetic counseling is essential; though ERT is primarily used in infants, future family planning discussions must consider the genetic nature of the disorder. Option A (Acid maltase deficiency \u2013 Pompe disease) aligns perfectly with the clinical scenario. Option B (Phosphofructokinase deficiency) typically presents with exercise-induced muscle cramps and does not account for the cardiomegaly or macroglossia seen here. 1. The combination of hypotonia, cardiomegaly, and macroglossia in an infant is almost pathognomonic for Pompe disease. 2. Early initiation of enzyme replacement therapy can significantly alter the disease course. 3. Elevated CK levels support the muscular involvement from glycogen accumulation. Recent advances in enzyme replacement therapy have improved the prognosis of infantile Pompe disease, and ongoing studies are exploring adjunct therapies and gene therapy options. Early diagnosis via newborn screening is increasingly being implemented in many countries.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "case of pt with cramp and stiffness that relive with movements, same hx in the father Diagnosis :",
    "option_a": "Thamson",
    "option_b": "Paramytonia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonia congenita is a channelopathy that results in delayed muscle relaxation after voluntary contraction. Thomsen disease is the autosomal dominant form of myotonia congenita. Mutations in the CLCN1 gene, which encodes the chloride channels in skeletal muscle, lead to membrane hyperexcitability and prolonged muscle contractions. Thomsen disease specifically shows the characteristic 'warm-up phenomenon,' where repeated activity leads to an improvement in stiffness. Patients typically complain of muscle cramps and stiffness that improves with repeated activity (warm-up phenomenon). A positive family history, as in the case where the father is also affected, strongly supports an autosomal dominant condition like Thomsen disease. In contrast, paramyotonia congenita (caused by sodium channel mutations) usually worsens with repeated activity and cold. The diagnosis is based on clinical history and can be confirmed by electromyography (EMG), which shows myotonic discharges. Differential diagnoses include other causes of muscle stiffness such as paramyotonia congenita, which has a different response to exercise and temperature. Management typically involves symptomatic treatment with drugs such as mexiletine, which can help alleviate myotonia. Avoidance of known triggers (e.g., cold, excessive exertion) is also recommended. In pregnancy and lactation, the safety profile of mexiletine should be carefully considered (currently categorized as a medication that should be used only if the potential benefits justify the risk), and alternative management strategies may be needed. Option A (Thomsen disease) is the correct diagnosis given the improvement of stiffness with repetitive movement (warm-up phenomenon) and the family history. Option B (Paramyotonia congenita) is less likely as it typically worsens with repeated activity, especially in cold environments. 1. The warm-up phenomenon is a hallmark of myotonia congenita, particularly Thomsen disease. 2. A positive family history is a key clue to its autosomal dominant inheritance. 3. EMG is instrumental in confirming the diagnosis. Recent studies have reinforced the efficacy of mexiletine in improving symptoms in myotonia congenita. Current guidelines also stress the importance of a careful family history and genetic counseling for affected families, especially when considering treatment in women of childbearing age.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "23 y/o male hx of respiratory failure, cerebral aneurysm,\n\nEMG : Mytonia without clinical mytonia\n\nWhat is the diagnosis",
    "option_a": "Pompe",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Pompe disease (glycogen storage disease type II) is a metabolic myopathy caused by a deficiency in the lysosomal enzyme acid \u03b1-glucosidase. This results in glycogen accumulation in tissues, especially in skeletal and respiratory muscles. The late\u2010onset form typically presents with slowly progressive proximal muscle weakness and respiratory insufficiency. The enzyme deficiency leads to the build\u2010up of glycogen within lysosomes, causing muscle fiber damage and dysfunction. In some reports, vascular smooth muscle involvement may underlie rare associations such as cerebral vascular abnormalities (including aneurysms) due to glycogen deposition affecting vessel walls. Moreover, on electromyography (EMG), electrical myotonia (i.e. myotonic discharges) can be detected even if clinical myotonia (delayed relaxation on grip) is not evident. A young patient with respiratory failure and a history of cerebral aneurysm fits the profile for late\u2010onset Pompe disease. The presence of electrical myotonia on EMG (without clinical myotonia) supports this diagnosis, differentiating it from classical myotonic dystrophies, where myotonia is often clinically apparent. Differential diagnoses include myotonic dystrophy (which usually presents with clinically evident myotonia, cataracts, and multisystem involvement), other metabolic myopathies, and channelopathies. Key diagnostic steps include measurement of acid \u03b1-glucosidase activity (with eventual genetic confirmation), creatine kinase levels (often mildly elevated), and muscle MRI. An enzyme assay in blood or fibroblasts is essential. First\u2010line treatment is enzyme replacement therapy (ERT) with alglucosidase alfa, which has been shown to slow disease progression. Supportive treatments include physical therapy, respiratory support, and nutritional management. In pregnancy and lactation, careful consideration is needed; while data are limited, the potential benefit of ERT may outweigh risks in severe cases with multidisciplinary input. Regular monitoring of respiratory function and muscle strength is key. Option A (Pompe disease) is correct because it accounts for the respiratory failure, possible cerebral vascular involvement, and the characteristic finding of electrical myotonia on EMG without overt clinical myotonia. The marked answer (B) is incorrect as it does not match the clinical\u2013electrophysiologic profile. 1. Late\u2010onset Pompe disease may present with isolated respiratory failure and proximal muscle weakness. 2. EMG can reveal electrical myotonia even when clinical myotonia is absent. 3. Enzyme replacement therapy is the cornerstone of management. Recent guidelines emphasize early diagnosis and initiation of ERT to preserve muscle and respiratory function. Ongoing research into adjunctive therapies and optimal timing of intervention continues to refine management strategies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Post bariatric surgery done 6 months back, and symptom started 3 months back came with weakness, imbalance on exam loss of proprioception, spasticity, B12 and melanoic acid normal.",
    "option_a": "Zinc deficiency",
    "option_b": "B12 deficiency",
    "option_c": "Cu deficiency",
    "option_d": "Folate deficiency",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Copper deficiency myelopathy is a nutritional deficiency that can develop after bariatric surgery due to malabsorption. It typically presents with a clinical picture similar to vitamin B12 deficiency with dorsal-column dysfunction. Copper plays a critical role in the function of cytochrome oxidase and in the cross-linking of collagen and elastin, influencing myelination. Deficiency leads to demyelination, particularly affecting the dorsal columns and lateral corticospinal tracts, which results in a sensory ataxia and spasticity. Patients often present with symptoms of imbalance, loss of proprioception, and lower extremity spasticity. In this case, despite normal B12 and folate (melanoacetic acid) levels, the clinical presentation following bariatric surgery strongly suggests copper deficiency as the underlying cause. Key differentials include vitamin B12 deficiency (ruled out by normal levels), vitamin E deficiency, and other nutritional myelopathies. Establishing the diagnosis requires measuring serum copper and ceruloplasmin levels. Neurological imaging may show signal changes in the dorsal columns, similar to B12 deficiency. The first-line treatment is copper supplementation, typically administered orally if the deficiency is mild or parenterally if severe. Nutritional consultation is essential after bariatric surgery. In pregnant and lactating women, copper supplementation is safe and necessary if a deficiency is present, with doses adjusted according to current guidelines. Option C (Cu deficiency) is correct because it best explains the myelopathic syndrome (weakness, imbalance, loss of proprioception, spasticity) in the setting of normal B12 levels post\u2013bariatric surgery. Options A, B, and D are excluded by either lab normalcy (B12, folate) or lack of clinical feature relevance (zinc deficiency is not typically associated with this picture). 1. Bariatric surgery patients are at risk for multiple nutrient deficiencies, including copper deficiency. 2. Copper deficiency can mimic B12 deficiency neurologically. 3. Early recognition and supplementation can reverse or stabilize neurological deficits. Recent studies and consensus guidelines highlight the importance of routine micronutrient monitoring after bariatric surgery. Early copper supplementation has been shown to improve neurological outcomes, and current recommendations advocate for a multidisciplinary approach in monitoring and management.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Young male with hx of one side UL weakness progressive over 5 years then become started\nExamination involve all hand muscles with spearing brachioradilaus\n\nWhat is the other associated features:",
    "option_a": "nalysis provided shows that additional associated features like UMN signs, sensory deficits, bulbar symptoms, bilateral early involvement, or rapid progression are not characteristic of this anterior horn cell disorder. Therefore, the correct answer is 'None' (represented here by the marked answer B), and all other options are inconsistent with the clinical presentation.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a focal motor neuron disorder, classically recognized in conditions like Hirayama disease. It involves the anterior horn cells and is typified by unilateral or asymmetric upper limb weakness over several years, with a characteristic sparing of the brachioradialis muscle\u2014a phenomenon known as 'oblique amyotrophy.' Hirayama disease involves focal ischemic changes or mechanical compression in the lower cervical spinal cord due to neck flexion, leading to degeneration of anterior horn cells. The pattern of selective involvement, with sparing of certain muscles such as the brachioradialis, distinguishes it from more diffuse motor neuron diseases like ALS. Patients typically present with a slow, progressive weakness confined to one upper limb. Importantly, there are no upper motor neuron signs, sensory deficits, bulbar involvement, or rapid respiratory involvement \u2013 features that would suggest an alternative diagnosis like ALS. Differentials include amyotrophic lateral sclerosis (ALS), multifocal motor neuropathy, and other focal motor neuron disorders. MRI of the cervical spine, especially in neck flexion, can reveal forward displacement of the dural sac, supporting the diagnosis of Hirayama disease. EMG studies further confirm the anterior horn cell involvement. First-line management is conservative, including the use of a cervical collar to prevent neck flexion and progression of cord compression. Physical therapy can help maintain function. In selected progressive cases, surgical interventions such as anterior cervical decompression may be considered. In pregnant or lactating patients, conservative measures remain the mainstay due to the relative safety and noninvasive nature of treatment. The option analysis provided shows that additional associated features like UMN signs, sensory deficits, bulbar symptoms, bilateral early involvement, or rapid progression are not characteristic of this anterior horn cell disorder. Therefore, the correct answer is 'None' (represented here by the marked answer B), and all other options are inconsistent with the clinical presentation. 1. Hirayama disease typically affects young males with unilateral upper limb involvement that progresses slowly before stabilizing. 2. The sparing of the brachioradialis muscle ('oblique amyotrophy') is a classical sign. 3. The absence of UMN, sensory, and bulbar signs helps differentiate it from ALS. Recent research emphasizes the utility of dynamic cervical MRI studies (especially in flexion) for diagnosis. There is also ongoing investigation into the long\u2010term outcomes of conservative versus surgical management in Hirayama disease, with most current guidelines favoring conservative treatment in the early stages.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Filipino male pt came with hx of generalized weakness upon waking (Repeated many time in the common) What to order",
    "option_a": "potassium level",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario describes a Filipino male with episodes of generalized weakness primarily noted upon waking. This presentation is highly suggestive of a periodic paralysis, most notably thyrotoxic periodic paralysis, which is more common among Asian males. Thyrotoxic periodic paralysis is thought to result from excess thyroid hormone leading to increased Na+/K+ ATPase activity, which causes an intracellular shift of potassium. This results in transient hypokalemia and muscle weakness or paralysis. The episodes often occur after periods of inactivity, such as in the morning. The recurrent episodes of weakness, particularly in an Asian male, align with the expected demographic and clinical pattern of thyrotoxic periodic paralysis. Even though thyroid function tests are also important, the initial identification of an electrolyte disturbance (i.e., hypokalemia) is key to the diagnosis. The most common differential diagnoses include familial or hypokalemic periodic paralysis not associated with thyroid disease, and myasthenia gravis (which typically shows fatigable weakness but with ocular involvement). The first step is to check a serum potassium level during an acute attack, followed by thyroid function tests if hypokalemia is confirmed. In the acute setting, the first-line management is careful potassium supplementation to correct hypokalemia. Beta-blockers (like propranolol) may also be used acutely. Definitive treatment focuses on controlling the hyperthyroid state with antithyroid medications, radioactive iodine, or surgery, as appropriate. In pregnancy and lactation, antithyroid medications such as propylthiouracil (in the first trimester) followed by methimazole (in later trimesters) are used with caution while ensuring maternal and fetal safety, and potassium supplementation is managed carefully. Option A (potassium level) is correct because measuring serum potassium is the most appropriate initial investigation in a patient with episodic weakness suggestive of thyrotoxic periodic paralysis. The other options are not provided or relevant for the immediate evaluation of the electrolyte disturbance. 1. Thyrotoxic periodic paralysis is most common in Asian males and presents with episodic muscle weakness in association with hypokalemia. 2. Check serum potassium levels during an episode; subsequent thyroid function tests are crucial for diagnosis. 3. Prompt recognition and management of hypokalemia can prevent serious complications. Current guidelines recommend the rapid correction of hypokalemia in thyrotoxic periodic paralysis and early assessment of thyroid function. There is increasing emphasis on recognizing this condition in at-risk ethnic populations and a multidisciplinary approach to manage both the electrolyte disturbance and underlying thyroid dysfunction.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "young male, hx of generalized weakness, spring face and repository Examination: hypo reflexia Came to ER, received K supplements, later he repeated same attacks weekly K level 2.6 (low) What is the most accurate management",
    "option_a": "Acetazolamide",
    "option_b": "Mexiltine",
    "option_c": "Spironolactone",
    "option_d": "Daily potassium dose",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis is an episodic muscle disorder in which affected individuals develop transient episodes of muscle weakness associated with a low serum potassium level. It is classically a channelopathy that may be familial (commonly due to mutations in genes such as CACNA1S) or secondary to other conditions (e.g., thyrotoxicosis). The disorder results from abnormal ion channel function in skeletal muscle membranes. In familial cases, mutations disrupt calcium or sodium channel function leading to an abnormal shift of potassium into the cells, precipitating muscle fiber inexcitability during an attack. Triggers such as high carbohydrate meals, strenuous exercise, or stress may precipitate these episodes. Recent studies underline the genetic basis and variable penetrance associated with these channel alterations. Patients typically present with sudden, transient episodes of flaccid muscle weakness with hyporeflexia and serum potassium levels in the hypokalemic range (often <3.5 mEq/L). The weakness is typically generalized and may recur frequently if triggers continue and prophylactic measures are not implemented. Diagnosis is made by clinical history, laboratory investigations showing low serum potassium during attacks, and sometimes genetic testing. Differential diagnoses include thyrotoxic periodic paralysis (which requires evaluation of thyroid function), hyperkalemic periodic paralysis (with opposite electrolyte findings), and other neuromuscular disorders such as myasthenia gravis. Provocative testing and electromyography may help in difficult cases. Acute attacks are managed by careful potassium replacement (orally or intravenously) to correct the nadir without causing rebound hyperkalemia. For prophylaxis, first\u2010line therapy is a carbonic anhydrase inhibitor such as acetazolamide, which helps reduce attack frequency by stabilizing ion channel function. Second-line options may include potassium-sparing diuretics like spironolactone. In pregnancy and lactation, acetazolamide is generally avoided if possible in the first trimester; however, if the benefits outweigh the risks, it may be used with close monitoring, and alternative strategies such as lifestyle modifications and cautious potassium supplementation should be considered. Option A (Acetazolamide) is the correct prophylactic treatment because it decreases the frequency and severity of paralytic attacks in patients with familial hypokalemic periodic paralysis. Option B (Mexiletine) is typically used for myotonic conditions and is not the standard for periodic paralysis. Option C (Spironolactone), while a potassium-sparing diuretic, is a second-line option rather than first-line. Option D (Daily potassium dose) is not an ideal prophylactic measure as constant high potassium replacement can lead to rebound shifts and does not address the underlying channel dysfunction. 1. Always check serum potassium levels during an acute attack to guide treatment. 2. Acetazolamide is effective in reducing attack frequency in familial hypokalemic periodic paralysis. 3. Lifestyle modifications and avoidance of known triggers are important adjuncts to pharmacotherapy. Recent research supports the use of acetazolamide as a first\u2010line prophylactic agent in familial hypokalemic periodic paralysis. Current guidelines recommend genetic testing and individualized treatment plans\u2014especially considering potential complications during pregnancy\u2014to optimize patient outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "question regard Post polio",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "",
    "subspecialty": "Neuromuscular",
    "explanation": "Post-polio syndrome (PPS) refers to a condition occurring decades after the initial poliovirus infection, characterized by new muscle weakness, fatigue, and pain in previously affected or even unaffected muscles. The underlying mechanism in PPS is believed to be progressive degeneration of the anterior horn cells that survived the initial poliovirus insult. These motor neurons may have undergone compensatory reinnervation, and over time, the increased metabolic demand on these enlarged motor units leads to deterioration. Recent insights suggest that oxidative stress and age-related neuronal decline may also contribute. Patients with a history of poliomyelitis can present years later with new muscle weakness, increased fatigability, and sometimes pain. The pattern of weakness is typically related to the distribution of previously affected motor neurons, and symptoms are not due to an active infection but rather a gradual decline in motor unit function. The diagnosis of PPS is clinical and is based on a remote history of poliomyelitis, new onset of motor deficits, and supportive findings on electromyography (EMG) that typically show chronic denervation with reinnervation. Differential diagnoses include amyotrophic lateral sclerosis (ALS), other motor neuron diseases, or peripheral neuropathies, but the absence of sensory deficits and the long latency from the original poliovirus infection help distinguish PPS. Management is largely supportive. Physical therapy, energy conservation techniques, and appropriate use of assistive devices are the mainstays. There is no definitive pharmacological treatment currently accepted. In the context of pregnancy and lactation, supportive management is emphasized, with careful monitoring and individualized exercise programs recommended to maintain function without overexertion. The hypothetical correct option\u2014\u2018anterior horn cell degeneration\u2019\u2014accurately reflects the pathophysiological mechanism behind PPS. Options suggesting an active poliovirus infection, upper motor neuron lesions, peripheral neuropathy, or primary myopathy are incorrect; they do not align with the recognized mechanism of PPS. 1. PPS typically manifests decades after the initial poliomyelitis infection. 2. The disorder is due to chronic degeneration of anterior horn cells rather than a reactivation of the virus. 3. Management is supportive with an emphasis on physical therapy and energy conservation. Current research in PPS focuses on optimizing physical rehabilitation strategies and exploring neuroprotective agents; however, no disease-modifying treatments have been established. Guidelines emphasize a multidisciplinary approach to maximize function and quality of life.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "20s male hx of limbs weakness, in examination found to have significant weakness of posterior thigh and scapular muscles and winging of scapula, sparing face. Muscle biopsy showed esinophila\nWhat is the diagnosis:",
    "option_a": "calpin 2A",
    "option_b": "lamin 1B",
    "option_c": "calvin 1C",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Limb-girdle muscular dystrophies (LGMDs) are a group of disorders that primarily affect the shoulder and pelvic girdle muscles. LGMD type 2A, also known as calpainopathy, is one of the most common forms and is due to a mutation in the gene encoding calpain-3. LGMD2A is caused by mutations in the CAPN3 gene resulting in deficient or dysfunctional calpain-3, a muscle-specific protease that plays a role in sarcomere remodeling and muscle repair. This leads to progressive muscle fiber degeneration and a dystrophic pattern on muscle biopsy. The occasional presence of eosinophilic infiltrates may be noted in early stages, which can be a helpful histopathological clue. Patients usually present in their teens or 20s with progressive proximal muscle weakness, often affecting shoulder girdle (scapular winging) and posterior thigh muscles, while sparing the facial muscles. The clinical pattern helps to differentiate LGMD from other muscular dystrophies that often involve facial or distal muscles. Diagnosis is based on clinical examination, muscle biopsy showing dystrophic changes with eosinophilic infiltrations, and confirmed by genetic testing for CAPN3 mutations. Differential diagnoses include facioscapulohumeral muscular dystrophy (which involves facial weakness), Emery-Dreifuss muscular dystrophy (characterized by early contractures and cardiac involvement), and other forms of LGMD. There is currently no curative treatment for LGMD2A. Management is primarily supportive, including physical therapy to maintain mobility and prevent contractures, occupational therapy, and, when needed, orthopedic interventions. Corticosteroids are not routinely used in LGMD2A as their effectiveness is not clearly established. In pregnancy and lactation, a multidisciplinary team approach is recommended with careful consideration of physical rehabilitation and nutritional support. Option A ('calpin 2A') is intended to refer to calpainopathy (LGMD2A) and is therefore the correct diagnosis given the clinical and biopsy findings. Option B ('lamin 1B') suggests a laminopathy seen in Emery-Dreifuss dystrophy, which has a different clinical profile, and Option C ('calvin 1C') is not a recognized subtype in the established classification of LGMD. Option D is blank and does not provide an answer. 1. LGMD2A (calpainopathy) often presents with scapular winging and proximal muscle weakness while sparing the face. 2. Eosinophilic infiltrates on muscle biopsy can be a subtle but helpful diagnostic clue in LGMD2A. 3. Genetic testing remains the gold standard for diagnosis. Recent studies are exploring gene therapy and novel molecular treatments for LGMD2A; however, current management remains supportive. Updated consensus guidelines focus on early diagnosis through genetic analysis and individualized rehabilitative strategies to improve quality of life.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Long scenario of descending weakness start from face to repiratory then whole body (decending). NCS incremental response. What type of disease?",
    "option_a": "post synaptic disease",
    "option_b": "Presynaptic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Neuromuscular junction disorders impair the transmission of signals between motor nerve terminals and muscle fibers. They are broadly classified into presynaptic and postsynaptic disorders, with distinct pathophysiological mechanisms and electrophysiological features. In presynaptic disorders such as Lambert\u2013Eaton myasthenic syndrome (LEMS) or botulism, there is impaired acetylcholine release from nerve terminals often due to dysfunction of voltage-gated calcium channels. This deficit results in a low initial compound muscle action potential that can increase dramatically (incremental response) after brief exercise or high-frequency repetitive nerve stimulation. A descending pattern of weakness, starting with cranial nerve involvement (facial weakness) followed by respiratory and generalized weakness, is most suggestive of botulism; however, an incremental response on nerve conduction studies is classically seen in presynaptic disorders (observed in both LEMS and botulism). The clinical scenario here, combined with electrophysiological findings, supports a presynaptic defect. Electrophysiological studies are key in differentiating neuromuscular junction disorders. Repetitive nerve stimulation showing an incremental (facilitated) response is considered diagnostic of presynaptic dysfunction. Differential diagnoses include myasthenia gravis (postsynaptic disorder with decremental response) and primary muscle diseases. Ancillary tests (e.g., antibody testing in myasthenia gravis) help refine the diagnosis. Management depends on the specific presynaptic disorder. For LEMS, first-line treatments include 3,4-diaminopyridine to enhance acetylcholine release, with adjunctive immunomodulatory therapies if paraneoplastic or refractory. Botulism, on the other hand, requires prompt administration of antitoxin and intensive supportive care, especially respiratory support. Pregnancy and lactation considerations demand careful risk\u2013benefit analyses; for example, the use of 3,4-diaminopyridine in pregnancy lacks robust data, so decisions must be individualized. Option A (postsynaptic disease) is incorrect because a decremental response on repetitive nerve stimulation would be expected in postsynaptic disorders like myasthenia gravis. Option B (presynaptic) is correct as the incremental response seen on NCS is characteristic of presynaptic pathology. Options C and D are not provided and thus are not considered. 1. An incremental response on repetitive nerve stimulation is a key diagnostic indicator of presynaptic neuromuscular junction disorders. 2. Differentiation between presynaptic and postsynaptic disorders is critical for proper management. 3. Botulism, a presynaptic disorder, typically presents with a descending pattern of paralysis coupled with autonomic symptoms. Recent guidelines underscore the use of electrophysiological testing as a cornerstone for diagnosing neuromuscular junction disorders. Current research is focused on improving therapeutic options for conditions like LEMS, with studies investigating novel agents to enhance presynaptic acetylcholine release. In acute scenarios such as botulism, timely supportive care and antitoxin administration remain the gold standard.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "case hypokalemic periodic paralysis\nWhat help in diagnosis",
    "option_a": "Long exercise test",
    "option_b": "Short exercise test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis is a channelopathy characterized by episodic muscle weakness associated with low serum potassium levels. Electrophysiologic exercise tests can be used to unmask abnormalities in muscle excitability, with the long exercise test being particularly valuable. The disorder is most often due to mutations in ion channels (commonly calcium channels like CACNA1S) that regulate skeletal muscle electrical activity. The altered channel function leads to inappropriate depolarization and reduced excitability upon triggering events. Studies have shown that prolonged exercise in these patients results in a decremental response in compound muscle action potential, reflecting impaired repolarization and defective ion channel kinetics. Clinically, patients present with episodes of severe muscle weakness often triggered by high-carbohydrate meals, rest after exercise, or other metabolic stresses. The electrophysiologic long exercise test helps demonstrate a sustained decrement in muscle action potentials that correlates with the clinical episodes. Diagnosis is based on a combination of clinical history, serum potassium measurements during episodes, and electrodiagnostic studies. Differential diagnoses include hyperkalemic periodic paralysis, myasthenia gravis, and other muscle channelopathies. The long exercise test distinguishes hypokalemic periodic paralysis from myotonic disorders where short exercise tests may be informative. First-line management includes acute correction of hypokalemia during attacks with potassium supplementation and preventive measures avoiding trigger factors. Long-term treatment may involve carbonic anhydrase inhibitors (e.g., acetazolamide), which are generally considered safe in pregnancy with careful monitoring. Genetic counseling is recommended as these disorders are typically inherited in an autosomal dominant pattern. Option A (Long exercise test) is correct because it reliably elicits the decrement in muscle action potentials seen in hypokalemic periodic paralysis. Option B (Short exercise test) is more typically used for diagnosing myotonic disorders and is less useful in this condition. 1. Hypokalemic periodic paralysis is often precipitated by high carbohydrate intake and rest after exercise. 2. The long exercise test is a key diagnostic tool that documents a significant decrement in compound muscle action potentials. Recent guidelines emphasize the importance of electrophysiologic testing alongside genetic analysis for definitive diagnosis. Advances in understanding channel mutations continue to refine diagnostic criteria and help tailor therapeutic strategies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "adult with hx of gait issues\nExamination significant weakness and atrophy of gastrocnemius muscle with mild weakness in upper limbs\nWhat is the diagnosis:",
    "option_a": "dysferlin 2B",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathies are a group of muscular dystrophies caused by mutations in the dysferlin (DYSF) gene. They can manifest as either a distal myopathy (Miyoshi myopathy) or as limb-girdle muscular dystrophy type 2B, both characterized by muscle weakness and atrophy. Mutations in the dysferlin gene lead to impaired membrane repair mechanisms in muscle fibers. This results in progressive muscle fiber degeneration and replacement with fat and connective tissue, particularly impacting the gastrocnemius and other lower limb muscles. Patients typically present in early adulthood with gait abnormalities, calf (gastrocnemius) muscle weakness, and atrophy. Over time, there may be mild involvement of other muscle groups, including the upper limbs. Elevated serum creatine kinase (CK) levels are common. Diagnosis relies on a combination of clinical assessment, markedly elevated CK levels, electromyography (EMG), and definitive muscle biopsy with immunostaining for dysferlin. Genetic testing confirms the mutation. Differential diagnoses include other forms of limb-girdle muscular dystrophy (such as calpainopathy), inflammatory myopathies, and metabolic myopathies such as Pompe disease. Management is supportive with physical therapy, occupational therapy, and mobility aids as needed. There is currently no disease-modifying treatment. Regular monitoring of respiratory and cardiac function is advised. During pregnancy and lactation, supportive care remains the mainstay and multidisciplinary management is recommended, with careful obstetric assessment due to the potential impact of muscle weakness on pregnancy. Option A (dysferlin 2B) is correct because the clinical features of predominant gastrocnemius muscle atrophy with progressive involvement of other muscle groups align with dysferlinopathy, often manifesting as limb-girdle muscular dystrophy type 2B or Miyoshi myopathy. 1. Dysferlinopathies typically present with markedly elevated CK and may show a distinct pattern of calf muscle atrophy. 2. The disease spectrum can vary from distal myopathy (Miyoshi) to limb-girdle presentation (LGMD2B). Current research is focused on gene therapy and novel molecular interventions. However, the mainstay remains supportive management with a multidisciplinary approach as recent guidelines continue to stress symptomatic care and genetic counseling.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Smoker, with polyneuropathy\nP/Q Calcium Channel",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Unknown",
    "subspecialty": "Neuromuscular",
    "explanation": "P/Q-type calcium channels are integral for neurotransmitter release at the neuromuscular junction and are classically associated with Lambert-Eaton Myasthenic Syndrome (LEMS). However, when evaluating a smoker with polyneuropathy, it is important to differentiate between channelopathy-mediated syndromes and neuropathies due to toxic or metabolic causes. LEMS is an autoimmune disorder wherein antibodies target P/Q-type voltage-gated calcium channels, impairing acetylcholine release and leading to proximal muscle weakness and autonomic dysfunction. In contrast, smoking-related polyneuropathy is generally due to toxic, ischemic, or metabolic insults rather than autoimmune channel dysfunction. LEMS typically presents with fluctuating proximal muscle weakness and autonomic symptoms, not a classic polyneuropathy. The polyneuropathy observed in smokers is more likely to be a distal, symmetric sensorimotor deficit. Thus, the clinical presentation does not align with a direct P/Q calcium channel pathology. In a smoker with polyneuropathy, differential diagnoses include diabetic neuropathy, toxic neuropathy, nutritional neuropathies (e.g., vitamin B12 deficiency), and less commonly, paraneoplastic syndromes associated with lung cancer. Laboratory evaluations (including VGCC antibodies, if LEMS is suspected) and electrophysiologic studies help differentiate these conditions. For smoking-related polyneuropathy, the mainstay treatment remains smoking cessation and symptomatic management (such as neuropathic pain medications). In any patient with suspected paraneoplastic syndromes (e.g., LEMS associated with small cell lung cancer), oncologic evaluation is warranted. In pregnant and lactating patients, smoking cessation interventions are particularly important, and treatment options should be tailored to minimize fetal and neonatal exposure. While one might be tempted to link P/Q-type calcium channels with conditions in smokers because of the association of LEMS with small cell lung cancer, the context of a polyneuropathy does not support that connection. The answer 'Unknown' correctly reflects the current state of evidence, as there is no direct established relationship. Thus, the marked answer (if assumed to imply a specific channelopathy) is incorrect. 1. LEMS, not polyneuropathy, is associated with P/Q-type calcium channel antibodies. 2. Smoking-related neuropathies are most commonly toxic/metabolic rather than autoimmune channelopathies. Recent research and clinical guidelines clearly delineate the role of P/Q-type channels in LEMS, with no supportive evidence linking them to smoking-induced polyneuropathy. The emphasis remains on accurately matching clinical presentations with their underlying pathophysiology.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Paramyotonia",
    "option_a": "Sodium Channel (SCN4A)",
    "option_b": "Chloride",
    "option_c": "Potassium",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Paramyotonia congenita is a hereditary neuromuscular disorder characterized by episodes of myotonia (delayed muscle relaxation) exacerbated by cold and exercise. It is one of several channelopathies affecting skeletal muscle. The condition results from mutations in the SCN4A gene, which encodes the skeletal muscle sodium channel. These mutations affect the inactivation process of the channel, leading to sustained sodium influx and prolonged muscle fiber depolarization, particularly under cold conditions. Patients typically experience muscle stiffness and pain that worsen with exposure to cold or repetitive muscle activity. Symptoms often begin in childhood or early adulthood and may progressively affect daily activities. Diagnosis is based on clinical history, family history, and characteristic triggers (cold, exercise). Electromyography (EMG) can reveal myotonic discharges. Genetic testing for mutations in SCN4A confirms the diagnosis. Differential diagnoses include myotonia congenita (caused by chloride channel mutations) and other sodium channelopathies. First-line management involves avoiding triggers such as cold exposure and strenuous exercise. Pharmacologic treatment with sodium channel blockers like mexiletine can reduce myotonia; however, caution is advised in pregnant women due to limited fetal safety data, and non-pharmacologic strategies are preferred during pregnancy and lactation. Supportive care and physical therapy are also beneficial. Option A (Sodium Channel (SCN4A)) is correct because the genetic basis of paramyotonia congenita is well established as being due to mutations in the SCN4A gene. Options involving chloride or potassium channels do not apply to this condition. 1. Paramyotonia congenita\u2019s symptoms worsen with cold exposure, a distinguishing feature from other myotonias. 2. Genetic testing for SCN4A mutations is definitive for diagnosis. Recent studies have reinforced the role of SCN4A mutations in paramyotonia congenita. Ongoing research aims to develop more targeted therapies based on the molecular pathogenesis of sodium channel dysfunction.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Congenital Myasthenia gravis",
    "option_a": "Slow channel",
    "option_b": "Fast Channel",
    "option_c": "Dok7",
    "option_d": "Rapson",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited disorders that affect neuromuscular transmission. They are distinct from autoimmune myasthenia gravis and are classified based on the location and nature of the defect (eg, presynaptic, synaptic, or postsynaptic). The slow\u2010channel syndrome is one example of a postsynaptic defect. In slow\u2010channel congenital myasthenic syndrome, mutations in one of the subunits of the acetylcholine receptor (AChR) produce a gain\u2010of\u2010function defect. This results in prolongation of the channel opening, leading to excessive calcium influx, which in turn damages the postsynaptic membrane (endplate myopathy). The prolonged depolarization predisposes to repetitive muscle fiber firing and eventually results in muscle weakness. Patients typically present with fatigable, slowly progressive limb weakness and may also have ocular involvement. The abnormal channel kinetics produce a characteristic pattern on electrophysiological testing, with prolonged endplate potentials and a decremental response that can be demonstrated on repetitive nerve stimulation. Diagnosis is based on a combination of the clinical picture, electrophysiologic studies (eg, repetitive nerve stimulation, single-fiber EMG), and confirmation by genetic testing. Differential diagnoses include other CMS subtypes such as fast-channel syndrome (which has a shortened channel opening), Dok7-related CMS (often presenting with limb-girdle weakness and poor response to cholinesterase inhibitors), and rapsyn deficiency. Management of slow-channel syndrome is challenging. First-line treatments involve the use of cholinesterase inhibitors, although their benefit may be limited due to the nature of the channel defect. In some cases, open-channel blockers such as quinidine or fluoxetine have been trialed to reduce the excessive receptor activation. When treating women who are pregnant or lactating, the risks and benefits of these medications must be carefully weighed, and consultation with a specialist in maternal\u2013fetal medicine is recommended. Option A (Slow channel) is correct because it describes a congenital myasthenic syndrome in which prolonged AChR channel opening leads to endplate myopathy. Option B (Fast channel) is a distinct entity with abnormally short receptor activation but is not indicated here. Option C (Dok7) causes a different subtype of congenital myasthenic syndrome that often presents with limb-girdle pattern weakness and is usually resistant to cholinesterase inhibitors. Option D (Rapson, a variant spelling of rapsyn) is associated with receptor clustering defects and is one of the more common forms, but its presentation and inheritance pattern are different. 1. Slow-channel syndrome is characterized by prolonged endplate currents due to a gain-of-function mutation in the AChR. 2. It is inherited in an autosomal dominant pattern. 3. Targeted treatment (eg, use of open-channel blockers) may help reduce the calcium overload that damages the endplate. Recent research emphasizes the importance of genetic confirmation in CMS and is exploring targeted therapies that address the abnormal channel kinetics. Although cholinesterase inhibitors remain a mainstay of therapy, individualized treatment plans based on genetic subtype are becoming the standard of care, with special considerations needed for women who are pregnant or lactating.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Elderly with volar hand weakness ?? IBM",
    "option_a": "Rimmed vacuoles",
    "option_b": "Perifascicular atrophy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Inclusion Body Myositis (IBM) is an inflammatory myopathy that is unique in its overlap with degenerative processes. It predominantly affects older adults and has a distinct pattern of muscle involvement. IBM is characterized by endomysial inflammation with cytotoxic CD8+ T-cell invasion, along with degenerative changes including the presence of rimmed vacuoles and protein aggregates. These vacuoles represent autophagic processes and accumulated misfolded proteins. Patients typically present with slowly progressive muscle weakness that is asymmetric. In the upper extremities, volar forearm muscles (involved in finger flexion and grip) are frequently affected, while in the lower extremities, quadriceps weakness is common. This pattern helps differentiate IBM from other inflammatory myopathies. Diagnosis involves a detailed clinical assessment, elevated creatine kinase in many cases, and especially a muscle biopsy. The biopsy in IBM classically shows rimmed vacuoles along with endomysial inflammation. Differential diagnoses include polymyositis and dermatomyositis (which typically show perifascicular atrophy in dermatomyositis) and other myopathies. Currently, there is no effective immunosuppressive treatment that alters the course of IBM. Management is largely supportive and includes physical therapy, assistive devices, and attention to dysphagia if present. In elderly patients, management should also focus on maintaining function and quality of life. In pregnant or lactating women (although IBM is rare in this group), any immunomodulatory interventions must be carefully balanced against potential fetal risks. Option A (Rimmed vacuoles) is the correct histopathological finding in IBM. Option B (Perifascicular atrophy) is more typical of dermatomyositis and does not fit the presentation of IBM. The absence of additional options underscores that the key histologic clue for IBM is the presence of rimmed vacuoles. 1. IBM typically presents in older adults and often involves the forearm flexors, leading to volar hand weakness. 2. Rimmed vacuoles on muscle biopsy are pathognomonic for IBM. 3. IBM is often refractory to immunosuppressive therapy. Recent guidelines and studies continue to support the use of muscle biopsy for definitive diagnosis and underscore the limited role of immunotherapy in IBM. Research is ongoing regarding targeted therapies, but as of now, management remains primarily supportive.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "LGMD with positive family history in his sister and parents are first degree relative with multiple joint contractures",
    "option_a": "Dysferinlopathy",
    "option_b": "Calpainopathy",
    "option_c": "Laminopathy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Limb-girdle muscular dystrophies (LGMD) are a diverse group of disorders primarily affecting the pelvic and shoulder girdle muscles. They can be inherited in either an autosomal dominant or autosomal recessive pattern. Laminopathies result from mutations in the LMNA gene, which encodes nuclear envelope proteins lamin A/C. These proteins are essential for nuclear structural integrity. Mutations can lead to muscle fiber instability, early contractures, and often cardiac involvement. The presence of joint contractures, particularly in the relatives, is a clue to an LMNA mutation. In addition, a positive family history (as seen in the affected sister) supports an autosomal dominant transmission. Patients with laminopathy-related LGMD typically develop proximal muscle weakness along with early joint contractures (eg, elbows or Achilles tendons). Cardiac conduction defects may also be evident, necessitating regular cardiovascular screening. The family history with contractures makes this diagnosis more likely than other forms of LGMD. Diagnosis is based on clinical findings, family history, serum creatine kinase levels, and confirmed by muscle biopsy and molecular genetic testing. Differential diagnoses include dysferlinopathy (LGMD2B) and calpainopathy (LGMD2A), which usually have different patterns of muscle involvement and lack early joint contractures. Management of laminopathy-related LGMD includes supportive care with physical therapy to maintain muscle strength and joint mobility, and vigilant cardiac monitoring (often including echocardiography and ECG screening). In cases with cardiac involvement, treatment may include medications like ACE inhibitors or beta-blockers, and in some cases, pacemaker or defibrillator implantation may be needed. For women who are pregnant or lactating, cardiac medications should be chosen with safety profiles in mind and multidisciplinary management is essential. Option C (Laminopathy) is correct given the family history, early joint contractures, and the pattern of muscle involvement. Option A (Dysferinopathy) and Option B (Calpainopathy) are also causes of LGMD but are less likely to present with the pattern of joint contractures and positive family history described in this case. 1. Laminopathies (LMNA mutations) can present as LGMD with early joint contractures and a risk for cardiac involvement. 2. A thorough family history is essential in differentiating between the various LGMD subtypes. 3. Cardiac screening is critical in patients with LMNA mutations. Recent guidelines emphasize routine cardiac monitoring in patients with LMNA-related muscular dystrophy due to the risk of sudden cardiac death. Advances in genetic testing have improved diagnostic accuracy and allowed for more tailored management, which is particularly important for women of child-bearing age to ensure safe management during pregnancy and lactation.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Facioscapulohumeral case and ask about the diagnosis",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Facio",
    "subspecialty": "Neuromuscular",
    "explanation": "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic neuromuscular disorder that primarily affects the facial and scapular (shoulder) muscles. It is one of the most common muscular dystrophies and is usually inherited in an autosomal dominant pattern. FSHD is most commonly due to a deletion in the D4Z4 region on chromosome 4q35, which leads to the abnormal expression of the DUX4 gene. This aberrant expression is toxic to muscle cells, leading to progressive muscle degeneration. In some cases, mutations in the SMCHD1 gene can modulate the severity of the disease. The hallmark clinical features include weakness of the facial muscles (resulting in difficulty with eye closure and expression), scapular winging, and upper arm weakness. The disease typically follows a slowly progressive course. Differential diagnosis includes other muscular dystrophies (such as Duchenne or limb-girdle forms), myasthenia gravis, or motor neuron disease; however, the pattern of facial and shoulder weakness is distinctive for FSHD. Diagnosis is largely clinical, supported by the family history and characteristic pattern of weakness. Genetic testing confirming the contraction in the D4Z4 repeats or identifying SMCHD1 mutations is the gold standard for confirming FSHD. Differential diagnostic considerations include: Duchenne muscular dystrophy (which starts in early childhood and predominantly affects boys), limb-girdle muscular dystrophy (which typically spares the face), myasthenia gravis (which has fluctuating weakness and ocular symptoms), and motor neuron disease (which features both upper and lower motor neuron signs). There is currently no cure for FSHD. Management is supportive and includes physical therapy, occupational therapy, and sometimes surgical interventions (eg, scapular fixation) to improve function. Cardiac and respiratory screenings are generally normal in FSHD, but periodic monitoring is recommended. In pregnant or lactating women with FSHD, management remains supportive with careful monitoring of respiratory function and the potential impact on daily living, with multidisciplinary care as needed. The marked answer, referring to Facioscapulohumeral muscular dystrophy (FSHD), is correct. Incorrect options that might be considered include Duchenne muscular dystrophy (which has an earlier onset and predominantly affects males), limb-girdle muscular dystrophy (which does not typically involve the face), myasthenia gravis (which is an autoimmune disorder with fluctuating weakness), and motor neuron disease (which has both upper and lower motor neuron features, not the pattern seen in FSHD). 1. FSHD classically presents with facial weakness and scapular winging. 2. Genetic testing confirming D4Z4 repeat contraction is key for diagnosis. 3. It is inherited in an autosomal dominant pattern. Recent advances in molecular genetics have refined the diagnosis of FSHD. Ongoing research is evaluating gene-modulating therapies, though current management remains supportive. The updated guidelines stress the importance of early diagnosis and multidisciplinary management to improve patients\u2019 quality of life, including considerations for women during pregnancy and lactation.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]